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Introduction 
For many years, the process of voluntary informed consent for adult clinical research 
subjects has been widely accepted, standardized, and federally regulated. In comparison, 
adolescent clinical research subjects were not afforded the same privileges. Within the past 
decade there has been an increase in the number of pediatric and adolescent clinical research 
trials in the United States (NCCF 2000). Consequently, the moral and ethical implications of 
clinical research on minors has become a widely discussed issue and the notion of adolescent 
assent- a minor's affirmative agreement to participate in a clinical research trial- has been 
recognized. The purpose of this paper is to discuss the current and future use of adolescent 
assent in clinical research trials. 
What is informed consent? 
To best understand the need for adolescent assent, it is necessary to first understand the 
adult informed consent process and discuss its history, required elements, and relevance. The 
process of informed consent arose from the idea of bodily autonomy. Specifically, the notion of 
informed consent comes from the Nuremberg Code, which was adopted after the horrific 
discovery of research conducted by the Nazi party on prisoners of war. The Nuremberg Code 
begins by stating, "the voluntary consent of the human subject is absolutely essential." The 
Code goes on to address many of the issues that are now required elements of an informed 
consent. The Code cru1 be viewed as Appendix A. 
In 1964, the World Health Organization recognized the need to better provide guidelines 
that govern biomedical research and clinical trials. At their conference, the Declaration of 
Helsinki was unveiled which detailed ethical principles for medical research involving human 
• .. .. r 
f 
subjects. The Declaration serves as a "subject bill of rights" and gives subjects the right to 
ongoing information during the trial. The Declaration is attached as Appendix B. 
Today's informed consent is the ongoing process by which an investigator and study staff 
explains, answer questions, assess participant understanding, and document a subject's 
agreement to participate in a clinical trial. Informed consent is always obtained prior to the start 
of any study related procedures and must be documented in the subject's medical chart. Per the 
Code of Federal Regulations (2002), the informed consent process must include a discussion of 
certain elements that outline the trial and help the subject better understand the risks, benefits, 
alternative procedures, and purpose of the study. The discussion can include family members 
and, in fact, some institutions encourage subjects to bring the consent home for review prior to 
The informed consent process is ongoing throughout a subject's participation in the I f signature. 
study. Subjects are always informed of new information and informed consent forms are altered 
to reflect significant changes to the study design or protocol. As provided by the Nuremberg 
Code, informed consent to participate in a research trial is voluntary and may be withdrawn at 
any time. Informed consents for adult patients should be generated at an s'h grade reading level 
and should be in the subject's natural language. There are 14 required elements of informed 
consent as directed by 21 CFR Subpart B 50.25. These are listed in Appendix C. 
Adolescents in research 
The increase of adolescent participation in clinical research stems from the 1994 Food 
and Drug Administration (FDA) final rule designed to ensure that new drugs and biological 
products contain adequate pediatric labeling for the approved indications. The final rule 
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establishes that all new drugs and biologics will be studied in pediatric patients, and states that 
pediatric patients should not be excluded from pharmaceutical studies based solely upon 
inclusion into this population. The rule also authorizes the FDA to require pediatric studies of 
those marketed drugs and biological products that: (I) are used in a substantial number of 
pediatric patients for the claimed indications, and where the absence of adequate labeling could 
pose significant risks; or (2) would provide a meaningful therapeutic benefit over existing 
treatments for pediatric patients, and the absence of adequate labeling could pose significant 
risks to pediatric patients (21 CPR Parts 201, 312, 314 and 601). Additionally, the FDA argues 
that many diseases only affect children and it is, therefore, only appropriate that children 
participate in these trials to assure proper dosing and administration of medicine as well as 
growth and psychosocial side effects. 
While the concept of adolescents in research is new, studying adolescents in the medical 
setting is not. Clearly documented are problems regarding follow up, noncompliance, continuity 
of care, trusting relationships, and confidentiality (Wilson 2000). Pharmaceutical companies and 
physicians rely heavily on patient reported symptoms, medication usage, and side affects. 
Including adolescents in research studies must be carefully weighed by the physician, in 
cooperation with parents, to determine if the adolescent is capable or likely to adhere to a study 
regimen. 
Federal regulations 
In contrast with current physician ideology and Health and Human Services (HHS) 
policy, current federal regulations require only parental consent for all clinical drug trials. The 
FDA does recommend obtaining adolescent assent if possible but does not specify the age from 
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which assent is required nor the form the assent process should take. Specifically, 21 CFR 
Subpart D 50.55 states that "In addition to the determinations required under other applicable 
sections of this subpart D, the IRB must determine that adequate provisions are made for 
soliciting the assent of the children when in the judgment of the IRB the children are capable of 
providing assent." The Code continues by stating that the principal investigator and the 
Institutional Review Board (IRB) are left to determine the psychological state and maturity of the 
child, the type of assent issued and, ultimately, the need for assent. 
According to the Code, assent is defined as "a child's affirmative agreement to participate 
in research," and should be sought in addition to parental informed consent or permission if the 
minor adolescent is sufficiently able to understand the nature of participation in the clinical trial 
( 45 CRF Part 46). The crafting of an assent process should be viewed as a collaborative effort 
between investigator and the IRB. Due to the vague doctrine in the Code, regulation by IRBs is 
not standardized. IRBs are panels of medical specialists, nurses, social workers, and patient 
advocates who review clinical trial protocols, informed consents, patient information, and 
proceedings at institutions that conduct medical research. Each IRB has its own requirements for 
how trials can be conducted and what information must be provided to participants. Therefore, 
assent requirements vary greatly from institution to institution. 
Although there is no federal mandate or standardization, several pediatric groups have 
issued recommendations regarding adolescent assent. The Department of Health and Human 
Services published an Institutional Review Board Guidebook that states "L1.e cl-tild should be 
given an explanation of the proposed research procedures in a language that is appropriate to the 
child's age, experience, maturity, and condition. This explanation should include a discussion of 
any discomforts and inconveniences the child may experience if he or she participates." The 
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Federal Register (2000) also points out that distress is to be minimized for minors in clinical 
trials. Practices to consider to ensure minimal distress include staffing the trial with 
knowledgeable and skilled personnel with a specialty in pediatrics, having a physical setting 
conducive to the population (X-box games in lieu of Newsweek magazine), conducting the study 
in a familiar environment such as a routine clinic, and minimizing the number of blood draw 
attempts, sticks, and the amount of blood drawn. The Children's Health Act of2000 requires that 
all research involving children be in compliance with HHS regulations, and that there be a 
waiver ofthe FDA rule that disallows waivers for parental permission. 
Current overall exceptions to the parental permission rule in medicine vary state to state, 
but in most cases adolescent minors can give consent for pelvic examinations, screening for and 
treatment of sexually transmitted diseases, counseling for and prescribing of contraception, I 
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sexual abuse and mental health treatment, and HIV testing. Twenty-two states require r 
adolescent minors to notify parents prior to an abortion and nineteen states require parental 
consent prior to abortion. Nine states have no laws regarding the matter. Most states, however, 
require parental notification and some states require parental signature (Kendell 2000). 
The social obligation of adolescent assent 
It is now widely recognized that the doctrine of"informed consent" has only limited 
direct application to adolescent minors, as only patients can directly give informed consent for 
their care (Arnerican Association of Pediatrics 1995). In situations that require a parent or 
surrogate to make the decision, informed permission is provided by the parent and informed 
assent is provided by the minor adolescent patient. 
5 
As provided by the Nuremberg Code and Declaration of Helsinki, participation in clinical 
trials must be voluntary and the subject must remain informed throughout the study. Although 
the assent process is largely left up to the discretion of the investigator, the American Academy 
of Pediatrics (1995) agrees that IRBs and the investigator must consider how a subject's maturity 
will be assessed, who will obtain assent, where and when parental permission and child assent 
will be obtained, what types of assent documents will be used, whether signed assent will be 
requested, how the child's assent will be documented by the researcher, how it will be 
determined whether subjects/parents understand the research, and justification of a waiver of 
parental permission or child assent, if necessary. The Children's Hospital of San Diego and the 
Children's Hospital IRB were among the first to create an adolescent assent form (CCI/IRB 
1993). This form is widely used as a template (Appendix D). 
Providing adolescent assent assures elements of understanding regarding the clinical trial 
and fosters cooperation. The rights and dignity of the adolescent should be respected by 
empowering the adolescent with the knowledge needed to take part in his or her medical 
treatment (SlOP 2003). As adolescents become more autonomous in healthcare decisions and 
more knowledgeable about the field of medicine through television and the internet, physicians 
have been forced to abandon traditional paternalistic practices and better inform their patients of 
treatment options. In fact, healthcare is now seen as a partnership, where both the physician and 
patient make joint decisions and each has the right to agree or disagree to an action plan. Other 
societal disciplines, such as law, have already held adolescents to a higher ruoral and cognitive 
standard as is evidenced by the disturbing trend in criminal law to lower the age of responsibility 
for violent crimes and prosecuting these adolescents as adults (Aiken 2001 ). It is this concept of 
adolescent autonomy and self-responsibility that drives the notion of informed assent. 
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Other benefits to adolescent assent 
Adolescent assent encourages active participation in the medical decision process. 
Specifically, providing assent encourages understanding of the subject's illness, potential 
treatments, and the clinical trial while empowering the adolescent to ask questions and make 
determinations regarding his or her care. Giving the adolescent ownership of medical decisions 
will also foster compliance, a known issue with adolescents (Ziv 1999). Additionally, 
adolescents who have an active participation in the assent process are more likely to utilize 
physician offices for primary care rather than the emergency room (Wilson 2000). Adolescent 
assent also aides in breaking down other barriers to healthcare for adolescents, which include 
access to care, costs, confidentiality, privacy, confusing state and federal laws, and the ability to 
consent to care. Of these, disclosure of confidential information to parents and lack of 
understanding of state and federal laws are the biggest perceived obstacles by adolescents (Klein, 
1999 and 1998). 
Adolescent assent also has industry implications, in that it provides pharmaceutical 
companies and physicians with an insurance against future lawsuits of children injured while 
participating in clinical trials. Additionally, these companies and physicians expressed concern 
at the 1994 FDA hearings that ethical concerns of children were often overlooked in clinical 
practice and better standards should be set forth to ensure protection of rights. Pharmaceutical 
companies, more often than not, will provide an adolescent assent te1nplate for any clinical trial 
that emolls this population (CCI/IRB 1993). 
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The adolescent assent process 
As is the case with adult informed consent, the informed assent process implies more 
than just reading and signing a form. The informed assent process must include a discussion of 
the clinical research trial between the adolescent minor and the principal investigator. In most 
cases, explanation of consent and discussions last approximately 10 minutes per informed 
consent page (CCI 1993). After a thorough explanation of the procedures of the trial, the 
investigator must answer all questions of both the parent and the minor, ask questions to 
determine if the parent and the adolescent fully understand their risks, benefits, and treatment 
options, and make a final determination as to whether or not the participant understands the 
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pertinent information of the trial. Additionally, with adolescent subjects, an investigator and the 
IRB must determine (1) if the subject is a minor adolescent, (2) the subject's cognitive ability, 
(3) the level of confidentiality to be maintained and ( 4) how to obtain assent. 
The adolescent assent process - defining a minor adolescent 
According to state and federal law, persons under the age of 18 years are considered 
minors. In general, these patients cannot give informed consent about healthcare decisions for 
themselves. Instead, healthcare decisions are made by a parent or legal guardian. In an 
emergency, when a parent or legal guardian is unable to give consent, a physician assumes the 
responsibility of consent and uses his or her discretion regarding treatment of the minor. Those 
exempt from minor adolescent status include emancipated and mature minors. Emancipated 
minors are defined as adolescents who are married, pregnant, a parent, military, or self-
supporting. Mature minors are those deemed to have sufficient cognitive and psychological 
8 
maturity to make medical decisions as if they were 18 years or older. To become a mature 
minor, an adolescent must attend a judicial proceeding where a judge grants such status. 
The adolescent assent process- determining cognitive ability in minor adolescents 
Adolescent assent implies that the subject giving assent understand the benefits and risks 
of treatment- or of refusing treatment. As stated by the Code of Federal Regulations, IREs and 
investigators are to determine the adolescent's capability of providing assent. While cognitive 
development is one of the most expected aspects of a minor's growth and educational 
experience, development varies greatly between students of all socio-economic backgrounds 
making determination of true cognition a difficult task (ADOL 1997 ). 
A study by Tait eta! (1998) showed that children's perceived level of understanding of 
the elements of disclosure was significantly greater than their measured understanding. In fact, 
complete understanding of the elements of informed consent ranged from 30.4 to 89.4%. 
Children over the age of II had a significantly greater understanding with respect to the study 
protocol, potential benefits, and voluntary participation. 
Based upon similar studies, the National Commission for Protection of Human Subject of 
Biomedical and Behavioral Research (2001) established age 7 as the minimum age for involving 
children in the assent process. It is felt that most children this age can understand information 
tailored for their developmental level. Still, assessing children's maturity based solely on 
chronological age may not provide an accurate picture of their capacity to understand the 
research or to give assent. Therefore, the American Academy of Pediatrics recommends that 
assent "should usually be obtained from any child with an intellectual age [rather than 
chronological age] of7 years or more." 
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For adolescents, a normal teenager's development can be divided into three stages~ 
early, middle, and late adolescence (ADOL 2003). Early adolescence includes minors aged 12-
14 years. Generally, in this age group, adolescents are moving towards independence and 
struggle with a sense of identity. There is often moodiness, outbursts of feelings, and a 
distancing from parents. The early adolescent has improved speech abilities and is better able to 
articulate his or her ideas but is unable to have a sense of self direction and little regard for ethics 
or health status. Middle adolescence (15-16 years of age) is characterized by self improvement, 
vanity, and examination of priorities. These adolescents are most concerned with sexual 
attractiveness and feelings of intimacy. Ethically, middle adolescents begin their development of 
ideals and select role models. Middle adolescents will have a high interest in health as it relates 
to looking and feeling better. Late Adolescence, those aged 17-19 years, shows firmer identity, I 
! greater emotional stability, and self reliance. This group is able to delay gratification, is more 
concerned with the plight of others, and is capable of useful insight. These adolescents are often 
proactive about their moral and ethical obligations to society and their participation in preventive 
healthcare. 
The adolescent assent process ~maintaining confidentiality 
According to the American Academy of Pediatrics' Dr. Jenkins (2002), "Research has 
shown that a majority of adolescents voluntarily share information with their parents after they 
consult privately with their health provider." Additionaiiy, adolescents are more likely to seek 
routine healthcare ifthey can be assured that their confidentiality will be maintained (Thrall, 
2000). Together, physicians, parents, and adolescents should determine the type of disclosure 
(full, partial, none) that will occur between the physician and parent regarding the adolescent. 
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The Health Insurance Portability and Accountability Act of 1996 (HIP AA) includes privacy 
regulations for adolescents. The act is intended to assure patients that private health information 
will be kept confidential and only limited information will be disclosed for purposes other than 
patient care (HIP AA 1996). The rules currently allow parents access to the private health 
information of minor adolescents but can be overridden by more protective state and local laws. 
Due to the vagueness of the Act and lack of support from the current Bush administration, most 
physicians obey local laws but use their own discretion regarding whether or not to provide 
parents with information about basic care (American Medical Association 1998). 
In contrast to HIP AA regulations, the FDA requires parental permission and access to 
confidential records with regard to clinical trials. In a 2001 letter to the FDA, the National 
Human Research Protections Advisory Committee, a Division of the US Department of Health 
and Human Services (US DHHS), asked that "the FDA utilize an aggressive interpretation of the 
Food Drug and Cosmetic Act to enable mature adolescents to consent to involvement in certain 
types of important clinical studies without parental permission." The FDA replied that it was 
aware of the parental permission and confidentiality discrepancies between HHS, HIP AA, and 
the FDA but has made no means to decrease the disparities. 
The adolescent assent process - obtaining adolescent assent 
The National Childhood Cancer Foundation (2002) recommends that adolescent assent be 
obtained at the same time as parental consent. The Foundation maintains that consents are best 
presented to families in a simple and straight-forward manner. Discretion should be used when 
choosing the timing and location of when and where consent will be obtained so that the child 
and parents will be given an undistracted, ample amount of time to fully understand the purpose, 
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risks, benefits, alternate options, compensations, and other factors that may influence 
participation. The Foundation strongly believes that the decision should be family centered and 
not rushed or coerced by staff and that the subjects should not be overburdened with all of the 
information prior to a critical procedure. It is widely considered unfair to give an adolescent and 
family a diagnosis, begin discussing a trial, and push for consent on the same day. Rather, the 
entire family should be encouraged to ask questions and the researcher should not only answer 
questions but should also ask questions to assure understanding. 
The International Society of Pediatric Oncology (SIOP 2003) adds two more l 
F recommendations. In addition to the above, it states that children have a right to be treated with 
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L the best medical intervention available (regardless of parental permission issues) and that parents 
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do not have the exclusive right to be the sole decision maker. The Society pushes for court 
intervention when necessary for older adolescents and believes strongly that children of all ages 
should be included. 
If the subject's intellectual capabilities fall within the range of a 7-12 year old, a child 
information form should be required in addition to the parental permission form. The form ~-
~---
should be brief and specific, containing an explanation of the procedures, risks, and benefits. 
The form must be written in a language that is appropriate to the child's maturity and should not 
exceed 2 pages. Pictures and larger text should be used when possible (KID LINK). 
For adolescents over the cognitive age of 12 years, an adolescent assent form should be L 
used that mirrors the adult informed consent form (Appendix D). The assent process should 
include a candid discussion with the investigator about the risks, benefits, procedures, and 
treatment in the clinical research trial, the use of the assent form, a question and answer session, 
and a determination by the physician of the subject's understanding. 
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Elements in adolescent assent 
Although federal regulations do not dictate required elements of assent, the American 
Academy of Pediatrics (1995) has set forth it own criteria to aid IRBs and investigators. These 
are: (1) helping the patient achieve a developmentally appropriate awareness of the nature of his 
or her condition; (2) telling the patient what he or she can expect with tests and treatment (s); (3) 
making a clinical assessment of the patient's understanding of the situation and the factors 
influencing how he or she is responding (including whether there is inappropriate pressure to 
accept testing or therapy); ( 4) soliciting an expression of the patient's willingness to accept the f-
proposed care. Regarding this final point, the Academy notes that no one should solicit a 
patient's views without intending to weigh them seriously. The adolescent minor should be told 
upfront that dissent may still result in participation in the clinical trial. An adolescent's failure to 
object to assent should not be misconstrued as assent and the investigator should determine prior 
to the start of study procedures if the subject is truly assenting to the study. 
Adolescent dissent and parent permission 
The minor has the right to dissent at any time. Dissent, however, can be dismissed if 
either the minor is determined to be mentally or physically unable to provide assent or the 
research intervention is the only available treatment option. In this case, the parent permission or 
consent overrides the adolescent assent. Investigators conducting research must be sensitive to a 
subject who dissents and try to foster compliance and trust with that subject. Should the 
dissenting adolescent become uncooperative, difficult decisions must be made by the physician 
on how to proceed to assure that the adolescent remains informed and treated appropriately (Lim 
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2003). The American Medical Association's Policy H-60.965 states that parental consent should 
not be a barrier to adolescent care and that adolescent consent should be obtained whenever 
possible. 
In cases of minor adolescent dissent with parental permission, an information sheet 
should be provided to the minor adolescent. The information sheet should contain the same 
information as the assent form but with the signature removed. The investigator should 
acknowledge in the subject's medical chart that parental permission was obtained, adolescent 
minor permission was denied, and due diligence to inform the subject of participation was 
\ 
provided in the form of an information sheet (Lim 2003). ;---
The case against assent 
It has been argued that it is nearly impossible for an investigator to determine a minor's 
psychological capacity to know if assent should be provided, especially if the investigator is not 
the subject's primary care provider (Aiken 2001 ). It is equally hard to discern if adolescents are 
capable of making decisions that will affect them for the rest of their lives at an age when they 
are prone to vanity and social pressures. Noncompliance is a continual problem in adolescents, 
especially when the treatment regimen includes altering normal features (such as steroid use) 
(Thrall2000). To diffuse these arguments, an empirical study should be undertaken to determine 
the cognitive age at which adolescents comprehend the informed consent process for clinical 
trials. 
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Conclusion 
Once adolescent minors become capable of making autonomous decisions about their 
own beings, it is morally and ethically imperative that their decisions be solicited and respected. 
It is the responsibility of the FDA, HHS, American Academy of Pediatrics, and other interested 
parties to provide standardized guidance regarding the rights and protection of adolescent 
subjects just as is done for adults. Once there is clear direction and convergence from these 
governing bodies, a mandate for adolescent informed assent must be written into the Code of 
Federal Regulations to empower the adolescent research participants of the future. 
Inherent in clinical trial research is the affirmation that participation is voluntary and that 
the subject is made aware of the risks, benefits, and treatment options. With a current trend, via 
HIP AA and HHS, toward adolescent confidentiality, the need for assent is even greater to ensure 
that the minor adolescent is given every opportunity to be properly informed and permission 
granted for research. Informed assent is the vehicle that drives this autonomy for adolescent 
research participants. While the FDA, HHS, American Academy of Pediatrics, investigators, 
and IRBs agree that adolescent assent should be obtained whenever possible, there is little 
standardization across institutions regarding when, where, and how to obtain consent. 
It is agreed, however, that the assent process should include a determination if the subject 
is a minor adolescent, of the subject's cognitive ability, of the level of confidentiality to be 
maintained and how to obtain assent. Children with a cognitive age of7 or greater should be 
included in the assent process. The assent process must include a thoughtful discussion between 
the minor subject and the investigator regarding participation in research. For minor adolescents 
with a cognitive age 13-17 years of age, an adolescent assent form should be required that 
follows the format provided for adult consent but contains appropriate language relative to the 
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educational level of the youngest possible participant. The adolescent assent form must contain 
all 14 required elements of the informed consent as outlined in Appendix C. Specific focus 
should be placed on helping the patient fully understand the nature of his or her health condition, 
an explanation of what he or she can expect with tests and treatment, making a clinical 
assessment of the patient's understanding of the situation and the factors influencing how he or 
she is responding and a testament from the patient regarding the willingness to accept the 
proposed care. As is the case with adult informed consent, all assent processes must be fully 
documented in the subject's medical chart. Adolescent dissent must also be documented and 
appropriate steps taken to ensure that the adolescent's treatment is not compromised. 
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Appendix A 
NUREMBERG CODE 
1. The voluntary consent of the human subject is absolutely essential. This means that the 
person involved should have legal capacity to give consent; should be so situated as to be 
able to exercise free power of choice, without the intervention of any element of force, 
fraud, deceit, duress, over-reaching, or other ulterior form of constraint or coercion; and 
should have sufficient knowledge and comprehension of the elements of the subject 
matter involved as to enable him to make an understanding and enlightened decision. 
This latter element requires that before the acceptance of an affirmative decision by the 
experimental subject there should be made known to him the nature, duration, and 
purpose of the experiment; the method and means by which it is to be conducted; all 
inconveniences and hazards reasonable to be expected; and the effects upon his health or 
person which may possibly come from his participation in the experiment. The duty and 
responsibility for ascertaining the quality of the consent rests upon each individual who 
initiates, directs or engages in the experiment. It is a personal duty and responsibility 
which may not be delegated to another with impunity. 
2. The experiment should be such as to yield fruitful results for the good of society, 
unprocurable by other methods or means of study, and not random and uunecessary in 
nature. 
3. The experiment should be so designed and based on the results of animal experimentation 
and a knowledge of the natural history of the disease or other problem under study that 
the anticipated results will justify the performance of the experiment. 
4. The experiment should be so conducted as to avoid all unnecessary physical and mental 
suffering and injury. 
5. No experiment should be conducted where there is an a priori reason to believe that death 
or disabling injury will occur; except, perhaps, in those experiments where the 
experimental physicians also serve as subjects. 
6. The degree of risk to be taken should never exceed that determined by the humanitarian 
importance of the problem to be solved by the experiment. 
7. Proper preparations should be made and adequate facilities provided to protect the 
experimental subject against even remote possibilities of injury, disability, or death. 
8. The experiment should be conducted only by scientifically qualified persons. The highest 
degree of skill and care should be required through all stages of the experiment of those 
who conduct or engage in the experiment. 
9. During the course of the experiment the human subject should be at liberty to bring the 
experiment to an end if he has reached the physical or mental state where continuation of 
the experiment seems io him io be impossible. 
10. During the course of the experiment the scientist in charge must be prepared to terminate 
the experiment at any stage, if he has probable cause to believe, in the exercise of the 
good faith, superior skill and careful judgment required of him that a continuation of the 
experiment is likely to result in injury, disability, or death to the experimental subject. 
17 
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AppendixB 
Declaration of Helsinki 
It is the mission of the physician to safeguard the health of the people. His or her knowledge and 
conscience are dedicated to the fulfillment of this mission. The Declaration of Geneva of the 
World Medical Association binds the physician with the words, "The health of my patient will be 
my first consideration," and the International Code of Medical Ethics declares that, "A physician 
shall act only in the patient's interest when providing medical care which might have the effect of 
weakening the physical and mental condition of the patient. "The purpose of biomedical 
research involving human subjects must be to improve diagnostic, therapeutic and prophylactic 
procedures and the understanding of the etiology and pathogenesis of disease. In current medical 
practice most diagnostic, therapeutic or prophylactic procedures involve hazards. This applies 
especially to biomedical research. Medical progress is based on research which ultimately must 
rest in part on experimentation involving human subjects. In the field of biomedical research a 
fundamental distinction must be recognized between medical research in which the aim is 
essentially diagnostic or therapeutic for a patient, and medical research the essential object of 
which is purely scientific and without implying direct diagnostic or therapeutic value to the 
person subjected to the research. Special caution must be exercised in the conduct of research 
which may affect the environment, and the welfare of animals used for research must be 
respected. Because it is essential that the results of laboratory experiments be applied to human 
beings to further scientific knowledge and to help suffering humanity, the 
World Medical Association has prepared the following recommendations as a guide to every 
physician in biomedical research involving human subjects. They should be kept under review in 
the future. It must be stressed that the standards as drafted are only a guide to physicians all over 
the world. Physicians are not relieved from criminal, civil and ethical responsibilities under the 
law of their own countries. 
I. Basic Principles 
1. Biomedical research involving human subjects must conform to generally 
accepted scientific principles and should be based on adequately 
performed laboratory and animal experimentation and on a thorough 
knowledge of the scientific literature. 
2. The design and performance of each experimental procedure involving 
human subjects should be clearly formulated in an experimental protocol 
which should be transrnitted to a specially appointed independent 
committee for consideration, comment and guidance. 
3. Biomedical research involving human subjects should be conducted only 
by scientifically qualified persons and under the supervision of a clinically 
competent medical person. The responsibility for the human subject must 
always rest with a medically qualified person and never rest on the subject 
of the research, even though the subject has given his or her consent. 
18 
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Appendix B (continued) 
4. Biomedical research involving human subjects cannot legitimately be 
carried out unless tbe importance of the objective is in proportion to the 
inherent risk to the subject. 
5. Every biomedical research project involving human subjects should be 
preceded by careful assessment of predictable risks in comparison with 
foreseeable benefits to the subject or to others. Concern for the interests of 
the subject must always prevail over the interests of science and society. 
6. The right of the research subject to safeguard his or her integrity must 
always be respected. Every precaution should be taken to respect the 
privacy oftbe subject and to minimize the impact of the study on the 
subject's physical and mental integrity and on the personality of the 
subject. 
7. Physicians should abstain from engaging in research projects involving 
human subjects unless they are satisfied that the hazards involved are 
believed to be predictable. Physicians should cease any investigation if the 
hazards are found to outweigh the potential benefits. 
8. In publication of the results of his or her research, the physician is obliged 
to preserve the accuracy of the results. Reports of experimentation not in 
accordance witb the principles laid down in this Declaration should not be 
accepted for publication. 
9. In any research on human beings, each potential subject must be 
adequately informed of the aims, methods, anticipated benefits and 
potential hazards of the study and the discomfort it may entail. He or she 
should be informed that he or she is at liberty to abstain from participation 
in the study and that he or she is free to withdraw visor her consent to 
participation at any time. The physician should then obtain the subject's 
freely given informed consent, preferably inheriting. 
I 0. When obtaining informed consent for the research project tbe physician 
should be particularly cautious if the subject is in dependent relationship 
to him or her or may consent under duress. In tbat case the informed 
consent should be obtained by a physician who isn't engaged in the 
investigation and who is completely independent of this official 
relationship. 
II. In case of legal incompetence, informed consent should be obtained from 
the legal guardian in accordance with national legislation. Where physical 
or mental incapacity makes it impossible to obtain informed consent, or 
when the subject is a minor, permission from tbe responsible relative 
replaces that of the subject in accordance with national legislation. 
Whenever the minor child is in fact able to give a consent, the minor's 
consent must be obtained in addition to tbe consent of the minor's legal 
guardian. 
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12. The research protocol should always contain a statement of the ethical 
considerations involved and should indicate that the principles enunciated 
in the present declaration are complied with. 
Appendix B (continued) 
II. Medical Research Combined with Professional Care (Clinical Research) 
1. In the treatment of the sick person, the physician must be free to use a new 
diagnostic and therapeutic measure, if in his or her judgment it offers hope 
of saving life, re-establishing health or alleviating suffering. 
2. The potential benefits, hazards and discomfort of a new method should be 
weighed against the advantages of the best current diagnostic and 
therapeutic methods. 
3. In any medical study, every patient- including those of a control group, if 
any- should be assured ofthe best proven diagnostic and therapeutic 
method. 
4. The refusal of the patient to participate in a study must never interfere 
with the physician-patient relationship. 
5. If the physician considers it essential not to obtain informed consent, the 
specific reasons for this proposal should be stated in the experimental 
protocol for transmission to the independent committee (1, 2). 
6. The physician can combine medical research with professional care, the 
objective being the acquisition of new medical knowledge, only to the 
extent that medical research is justified by its potential diagnostic or 
therapeutic value for the patient. 
III. Non-Therapeutic Biomedical Research Involving Human Subjects (Non-Clinical 
Biomedical Research) 
1. In the purely scientific application of medical research carried out on a 
human being, it is the duty of the physician to remain the protector of the 
life and health of that person on whom biomedical research is being 
carried out. 
2. The subjects should be volunteers- either healthy persons or patients for 
whom the experimental design is not related to the patient's illness. 
3. The investigator or the investigating team should discontinue the research 
if in his/her or their judgment it may, if continued, be harmful to the 
individual. 
4. In research on man, the interest of science and society should never take 
precedence over considerations related to the well-being of the subject. 
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AppendixC 
Elements of Informed Consent 
1. A statement that the study involved research, an explanation of the purposes of the research 
and the expected duration of the subject's participation, a description of the procedures to be 
followed, and identification of any procedures that are experimental. 
2. A description of any reasonably foreseeable risks or discomforts to the subject 
3. A description of any benefits to the subject or to others that may reasonably be expected from 
the research. 
4. A disclosure of appropriate alternative procedures or courses of treatment, if any, that might 
be advantageous to the subject 
5. A statement describing the extent, if any, to which confidentiality of records identifying the 
subject will be maintained and that notes the possibility that FDA may inspect the records. 
6. For research involving more than minimal risk, an explanation as to whether any 
compensation and any medical treatments are available if i9njury occurs and, if so, what they 
consist of, or where further information may be obtained. 
7. An explanation of who to contact for answers to pertinent questions about the research and 
the rights of the research subjects, and who to contact in the event of a research-related injury 
to the subject 
8. A statement that participation is voluntary, that refusal to participate involves no penalty or 
loss of benefits to which the subject is otherwise entitled. 
The following additional elements, when appropriate, are also required: 
9. A statement that the particular treatment or procedure may involve risks to the subject (or the 
embryo or fetus, if the subject is pregnant or may become pregnant) that are currently 
foreseeable. 
10. Anticipated circumstances under which the subject's participation may be terminated by the 
investigator without regard to the subject's consent 
11. Any costs to the subject that may result from participation in the research. 
12. The consequences of a subject's decision to withdraw from the research and procedures for 
orderly termination of participation by the subject. 
13. A statement that significant new findings developed during the course of the research that 
may relate to the subject's willingness to continue participation will be provided to the 
subject. 
14. The approximate number of subjects involved in the study. 
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Title of Protocol 
AppendixD 
Adolescent Assent Form 
(ages 13-17) 
This is a research study. Research studies include only subjects who choose to take part. You are 
being asked to take part in this study because you have . . . . . . . . . . . . .. Please take your time to 
make your decision. Talk to your family about it. Be sure to ask questions about anything you 
don't understand. 
STUDY INVESTIGATOR AND SPONSOR 
Investigator: 
Sponsor: 
WHY IS THIS STUDY BEING DONE? 
This study is being done to find out ....... . 
WHAT MAKES THIS DIFFERENT FROM THE USUAL TREATMENT? 
The experimental part of this study is ......... (example: using the new drug called __ . This 
is an experimental drug because the Food and Drug Administration has not approved this drug 
to be used outside of a research studies like this one.) 
Another experimental part of this study is ... ..... (example: that you will be randomized into one 
of three study groups. Randomization is like tossing a coin to make a choice. Neither you or the 
study doctor will choose your study group; it will be a random choice.) 
HOW MANY PEOPLE WILL TAKE PART IN THE STUDY? 
_subjects will be in this study. 
HOW LONG WILL MY CHILD BE IN THE STUDY? 
You will be in the study for __ . 
You can stop being in the study at any time. But, if you decide to stop, we encourage you to talk 
to the research doctor first. 
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Appendix D Continued 
WHAT IS INVOLVED IN THE STUDY? 
This is what will happen if you are in this study: 
Study Visit 1: These tests will be done at this visit. 
Study Visit 2: These tests will be done at this visit. 
We will let you know if there are any changes to the study or any new information that may 
change your mind about being in this study. 
WHAT ARE THE RISKS OF THE STUDY? 
The most common side effects seen with are: 
Side effects seen less often are: 
If you get sick or have any problems from taking the study drug you should call your study 
doctor right away. If necessary, using the study drug may be stopped and other therapy may be 
started. 
Blood Draws: Possible side effects from blood drawing include: 
faintness, 
irritation of the vein, 
pam, 
bruising 
or bleeding at the blood draw site. 
There is also a slight possibility of infection or fainting. 
Using the numbing cream used for blood draws may cause pain, skin irritation, or the skin 
temporarily turning red, white or developing a rash. 
Other risks in this study include the following: 
Your condition may not improve, it may stay the same or it may get worse while you are in this 
study. There may be side effects or discomforts from the use of the study drug, that we don't 
know about yet. 
For more information about risks and side effects, ask your study doctor. 
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Appendix D (continued) 
For Girls: Are There Risks ifi Get Pregnant? 
There may be unknown risks to an unborn baby if you are pregnant and participate in this study. 
Sample wording: So, if you are having menstrual periods, you must use a study approved birth 
control method and agree not to try to get pregnant during the study. 
It is important that you contact the study doctor right away if you think you may be pregnant, if 
you have missed a period or it is late, or if you have a change in your usual menstrual cycle 
(heavier bleeding than usual or bleeding between periods). 
If you become pregnant during the study you will not be allowed to stay in the study. 
ARE THERE BENEFITS TO TAKING PART IN THE STUDY? 
Sample wording: We cannot promise that you will benefit from this research study. You may 
get better or you may get worse. Others may benefit from the information gathered from this 
study. 
WHAT OTHER OPTIONS ARE THERE? 
Sample wording: If you choose not to be in this study there are other options available that you 
can talk about with the doctor. Some other options are: 
WHAT ABOUT CONFIDENTIALITY? 
Every reasonable effort will be made to keep your medical records confidential. But we do have 
to let some people look at your study records and maybe your hospital records. These people can 
see your records: 
(sponsor) 
The FDA (US Food and Drug Administration) or governmental agencies in other countries 
where the study drug may be considered for approval 
The IRB (for the protection of human subjects in research) 
We will keep your records private unless we are required by law to share any information. The 
law says we have to tell someone if you might hurt yourself or someone else. The study doctor 
can use the study results as long as you cannot be identified. 
WHAT ARE THE COSTS? 
WHAT IF I AM INJURED IN THE STUDY? 
If you need to be treated for any research injury or illness from being in this study you will be 
given medical care. 
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Appendix D (Continued) 
WILL I GET PAID TO BE IN THIS STUDY? 
WHO DO I CALL IF I HAVE QUESTIONS OR PROBLEMS? 
For questions about the study or a research-related injury, call the researcher: 
Name and phone munber 
WHAT ARE MY RIGHTS AS A RESEARCH SUBJECT? 
Being in this study is voluntary. You don't have to be in this study if you don't want to or your 
can stop being in the study at any time. Leaving the study will not result in any penalty or loss of 
benefits that you have now. If you have questions about your rights you may call: 
Rebecca M. Clark, IRB Coordinator 
Institutional Review Board 
(858) 966-4008 
(which is a group of people who review the research to protect your 
rights) 
We will tell you about new information that may affect your health, welfare, or willingness to 
stay in this study. 
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Appendix D (Con tinned) 
AGREEMENT TO BE IN THE STUDY 
Your signature below means that you have read the above information about the --,-----,--
study and have had a chance to ask questions to help you understand what you will do in this 
study. Your signature also means that you have been told that you can change your mind later if 
you want to. You will be given a copy of this agreement and a copy of the Subject's Bill of 
Rights. By signing this assent form you are not giving up any of your legal rights. 
SIGNATURE OF SUBJECT (13 YRS & OLDER) DATE 
SIGNATURE OF PERSON WHO EXPLAINED THIS FORM DATE 
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Appendix D (Continued) 
ADOLESCENT SUBJECT BILL OF RIGHTS 
As a subject in a research, you have certain rights and responsibilities. It is important that you understand 
the nature and purpose of the research and that your consent be offered willingly. To help you understand, 
you have the following specific rights: 
I. To be told about the research and why it is being done. 
2. To be told about all procedures to be followed and of any drug or device to be used. 
3. To be told about any risks or discomforts, which can be reasonably expected to happen. 
4. To be told about any benefits you may expect as a subject of this research. 
5. To be told about any other options you have instead of this research. 
6. To be told about any medical treatments that are available to you if there are complications from 
this research. 
7. To be encouraged to ask questions and given a chance to ask any questions about the study or the 
procedures involved in this research. 
8. To be told that you can stop being in this research study at any time and that won't affect your 
medical care in any way. 
9. To be given a copy of the signed and dated written assent form. 
I 0. To not be pressured in any way to be in this research study or be pressured to choose not to be in 
this research study. 
If you have any more questions or are worried about your rights as a research subject, please call your 
research doctor or Rebecca Clark, IRB (human subjects) Coordinator at 858-966-4008 during normal 
working hours. 
SUBJECT SIGNATURE DATE 
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